The latest clinical data show that belzutifan can effectively improve progression-free survival (PFS) and symptom relief in patients with ccRCC by inhibiting HIF-2α activity, especially when combined with other targeted drugs (Jonasch et al., 2021; Choueiri et al., 2024; Song et al., 2024). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.